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Purpose. To compare the impact of prognostic factors of patients treated with deﬁnitive radio(chemo)therapy versus patients
treated with surgery and postoperative radiotherapy for squamous cell carcinoma of the oro- and hypopharynx. Patients
and Methods. 162 patients treated with deﬁnitive radiotherapy and 126 patients treated with postoperative radiotherapy were
retrospectively analysed. The impact of the prognostic factors gender, age, total tumor volume (TTV), pre-radiotherapy
hemoglobin level (Hb-level), tumor site, T- and N-classiﬁcation, radiotherapy interruptions >5 days, radiotherapy versus
simultaneous radiochemotherapy, R-status and time interval between surgery and radiotherapy were investigated. Results.
The median follow-up time for the censored patients treated with deﬁnitive radio(chemo)therapy was 28.5 months and for
postoperative radiotherapy 36.5 months. On univariate analysis, the TTV, Hb-level, and simultaneous radiochemotherapy had a
signiﬁcant impact on the survival of patients treated with deﬁnitive radio(chemo)therapy. For patients treated with postoperative
radiotherapy, only the TTV showed a statistical trend for the survival (P = 0.13). On multivariate analysis, the TTV and
simultaneous radiochemotherapy maintained their statistical signiﬁcance for patients treated with deﬁnitive raditherapy, and
the TTV, the statistical trend for patients treated with postoperative radiotherapy (P = 0.19). Conclusions. The TTV was the
predominant prognostic factor for both, patients treated with deﬁnitive or postoperative radiotherapy.
1.Introduction
Squamous cell carcinoma of the head and neck (SCCHN) is
the ﬁfth most common neoplasm with an estimated annual
global incidence of more than 500,000 cases diagnosed
worldwide [1]. The treatment is usually interdisciplinary
and mainly involves surgeons, radiation oncologists, medical
oncologists, clinical nurse specialists, speech and language
specialists, and dieticians [2]. Dependent on the situa-
tion, goals of the treatment can be to obtain (i) a high
locoregional control and survival rates in patients with
limited disease, (ii) an increased survival in patients with
advanced disease (improved locoregional control, reduced
probability of distant metastasis, and second malignancies),
(iii) an increased organ-function preservation in resectable
and unresectable tumors, and (vi) an increased therapeutic
ratio (cure/toxicity ratio) [3]. Single modality treatment
is recommended for the patients with early-stage disease
(stage I or stage II, approximately 40% of the patients with
SCCHN) and combined modality treatment for patients
with locally advanced disease. The combined modality treat-
ment may include surgery followed by adjuvant radiother-
apy or radiochemotherapy, concomitant radiochemotherapy
(using conventional or alternative fractionation regimen),
and induction chemotherapy followed by radiotherapy or
radiochemotherapy [3, 4].
A precise understanding of prognostic factors is impor-
tant to select the optimal treatment for the individual
patient or to stratify patients for clinical trials or statistical
analyses. In this retrospective single-institutional study, the
role of potential prognostic factors was evaluated and
compared in patients with squamous cell carcinoma of2 Journal of Oncology
the oro- and hypopharynx after treatment with deﬁnitive
radiotherapy/radiochemotherapy (dRT) versus surgery fol-
lowed by postoperative radiotherapy (pRT).
2. Patientsand Methods
Between 1992 and 2000, 288 patients with squamous cell
carcinoma of the oropharynx or hypopharynx received a
radiation therapy as deﬁnitive (n = 162) or as postoperative
(n = 126) treatment.
Eligibility criteria for this retrospective single-institu-
tional study were histologically proven squamous cell car-
cinoma of the oropharynx or hypopharynx, no distant
metastasis or synchronous cancer at time of diagnosis, and
deﬁnitive or postoperative radiotherapy with a minimum
total dose of 60Gy.
2.1. Radiation Therapy and Simultaneous Chemotherapy.
One hundred and thirty-eight of 162 (85%) patients treated
with deﬁnitive radiotherapy received a concomitant boost
fractionation regimen, and 24 (15%) were treated with
conventional fractionation (single fraction dose of 2Gy, one
fraction a day, ﬁve fractions a week). Two concomitant boost
regimen were used: Regimen 1 consisted of a total dose of
66Gy in ﬁve weeks with a daily fraction dose of 2Gy and
a concomitant boost of 1.6Gy during the last two weeks
(n = 76)andregimen2ofatotaldoseof69.9Gyin5.5weeks
with a daily fraction dose of 1.8Gy and a concomitant boost
of 1.5Gy during the last 2.5 weeks (n = 62).
Ninety-four of 138 (68%) patients treated with concomi-
tant boost fractionation regimen received a simultaneous
chemotherapy as well as ﬁve (4%) patients treated with
conventional fractionation.
The simultaneous chemotherapy consisted of 70mg/m2
Carboplatin on days 1–5 and 29–33 (n = 73) or 70mg/m2
Carboplatin and 600mg/m2 5-ﬂuorouracil on days 1–5 and
29–33 (n = 26). Carboplatin was administered as a daily
short-term intravenous infusion and 5-ﬂuorouracil as an
intravenous continuous infusion for 120 hours.
For the postoperative radiotherapy, only conventional
fractionation without simultaneous chemotherapy was used
(n = 123).
The radiotherapy was performed with opposed lateral
ﬁelds for the upper neck and one anterior ﬁeld for the lower
neck using 6MeV photons. Patients were treated in a ther-
moplastic mask for immobilization, and individual blocks
were used to spare normal tissue where possible. After a dose
of 30 to 36Gy to the reference point, the spinal cord was
spared out of the photon ﬁelds and the uninvolved posterior
neck treated with electrons of selected energy according to
CT ﬁndings with daily doses of 2.5Gy ﬁve times a week
to the prescribed total dose. Target volumes were deﬁned
on CT scans, and the dose was calculated to midplane. In
selected patients, three-dimensional treatment planning was
performed and conformal treatment techniques used.
2.2. Quantitative Determination of the Total Tumor Volume
(TTV) from Digitised CT Scans. Pre-treatment CT scans of
all patients were digitized with an automatic laser scanner
(FIPS PLUS). The stored images were transferred to a
personal computer. The macroscopic tumor shape (primary
tumor and locoregional lymph node metastases) was deﬁned
in every CT slice (slice thickness 5mm or 8mm) using a
drawing tool (software: photostyler). The number of pixels
n enclosed by this contour was determined with a custom-
shapedimageprocessingprogram(software:InteractiveData
Language).TheareaAi oftheithslicewasdeterminedasAi =
pixel size (length)∗pixel size (width)∗n. The pixel size was
determined using the scaling as given on the CT-hardcopy.
The determined tumor area of each slice was multiplied with
its slice thickness di. The TTV was approximated by
Vtumor

cm3
=
m 
i−1
Ai

mm2
×di(mm)/1000. (1)
No interpolation between the CT slices was performed.
Repeated measurements using irregularly shaped tumor
phantoms showed a diﬀerence between the reference vol-
umes and CT-based volume measurements depending of the
slice thickness (5mm or 8mm) of 1.4% to 4.5%.
2.3. Estimation of the Total Tumor Volume (TTV) Based on
the Postoperative Histopathological Report. In addition to
the quantitative tumor volumetry based on digitised pre-
treatment CT scans, TTV was estimated based on the
postoperative histopathological report in patients treated
with adjuvant radiotherapy. The TTV was approximated
using the equation V = 4/3 π ∗ a ∗ b ∗ c,w h e r ea, b,a n dc
represent the orthogonal maximal tumor diameters.
2.4. Statistical Analysis. T h eo v e r a l ls u r v i v a lw a sd e ﬁ n e da s
the time between the ﬁrst day of the treatment and death
of any cause. The overall survival was estimated using the
Kaplan-Meiermethod,andtreatmentgroupswerecompared
using a two-sided log rank test. The locoregional failure-free
survival was deﬁned as the time between the ﬁrst day of the
treatment and a locoregional failure. The distant metastasis-
free survival was deﬁned as the time between the ﬁrst day
of the treatment and a distant failure. The locoregional
failure-free survival and the distant metastasis-free survival
were estimated by the cumulative incidence method, and
treatment groups were compared using the Gray test [5, 6].
The simultaneous relationship of multiple prognostic
factors to overall survival was assessed using Cox’s propor-
tional hazard regression analysis. The simultaneous relation-
ship of multiple prognostic factors to locoregional failure-
free or distant metastasis-free survival was assessed using the
hazards of the cumulative incidence function model [7].
To estimate the reliability of the tumor volumetry, the
TTV derived from digitised pretreatment CT scans was
compared with the TTV derived from calculations based
on tumor diameters provided by the postoperative histo-
pathological report of the same patients. For the method
comparison, the limits of agreement were estimated as des-
cribed by Bland and Altman [8].Journal of Oncology 3
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Figure 1: Impact of the total tumor volume (TTV) on overall sur-
vival in patients treated with deﬁnitive radiotherapy/radiochemo-
therapy.
3. Results
The median follow-up time for the censored patients treated
with deﬁnitive radiotherapy/radiochemotherapy was 28.5
months and for the patients treated with adjuvant post-
operative radiotherapy 36.5 months. The 5-year overall
survival for the patients treated with deﬁnitive radiother-
apy/radiochemotherapy was 0.27 (95% CI 0.18–0.35) and
for the patients treated with postoperative radiotherapy, 0.69
(95% CI 0.59–0.79).
The patient and treatment characteristics are demon-
strated in Table 1. Patients treated with deﬁnitive radiother-
apy/radiochemotherapy had a greater proportion of stage
4 tumors (96.9% versus 66.9%), a much larger median
TTV (68.4cm3 versus 21.2cm3), and a lower proportion of
preradiotherapy hemoglobin level ≤12g/dL (17.6% versus
4 2 . 6 % ) .T h er e d u c e dH bl e v e lw a sp r o b a b l yd u et os u r g e r y -
related blood loss. The performance status was not consid-
eredinthisstudybecauseitwasnotconsistentlydocumented
in the patient ﬁles.
3.1. Deﬁnitive Radiotherapy/Radiochemotherapy. On uni-
variate analysis, the TTV (Figures 1 and 2) and the pre-
radiotherapy hemoglobin level had a statistically signiﬁcant
impact on the overall survival and on the locoregional
control of patients treated with deﬁnitive radiotherapy/
radiochemotherapy. Simultaneous chemotherapy had a sta-
tistically signiﬁcant eﬀect on the overall survival and on
the incidence of distant metastasis. In addition, there
was a statistical trend of an association of simultaneous
chemotherapy with the locoregional control (P = 0.08).
The N-classiﬁcation had a statistically signiﬁcant impact on
locoregional control but no signiﬁcant impact on the overall
survival or metastasis-free survival. The results of the uni-
variate analysis are summarized in Table 2.O nm u l t i v a r i a t e
analysis, only the TTV and the simultaneous chemotherapy
maintained their statistical signiﬁcance (Table 3).
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Figure 2: Impact of the total tumor volume (TTV) on locore-
gional control in patients with deﬁnitive radiotherapy/radiochemo-
therapy. CIF: cumulative incidence function.
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Figure 3: Impact of the total tumor volume (TTV) on locoregional
control in patients treated with postoperative radiotherapy. CIF:
cumulative incidence function.
3.2. Postoperative Radiotherapy. On univariate analysis, the
TTV had a statistically signiﬁcant impact on the locoregional
control (Figure 3). The N-classiﬁcation had a statistically
signiﬁcant impact on the incidence of distant metastasis and
a statistical trend on the locoregional control (P = 0.06).
The results of the univariate analysis are summarized in
Table 4. On multivariate analysis, only the TTV (P = 0.05)
maintained its statistical signiﬁcance (Table 5).
3.3. Tumor Volumetry Method Comparison. The TTV was
estimated using quantitative tumor volumetry of digitized
pre-treatment CT scans in all patients. In addition to the
CT-based volumetry, in 34 patients, the TTV was also
estimated based on tumor diameters reported in the histo-
pathological report. The tumor volumes based on the two
methods were compared to estimate the precision of the4 Journal of Oncology
Table 1: Patient characteristics.
Characteristics
Deﬁnitive RT Postoperative RT
n % n %
Gender
Female 17 10.5 19 15.1
Male 145 89.5 107 84.9
Age (years)
≤56 87 53.7 72 57.1
>56 75 46.3 54 42.9
Hemoglobin level pre-RT (g/dL)
≤12 27 17.6 46 42.6
>12 126 82.4 62 57.4
Tumor site
Oropharynx 95 58.6 68 54.0
Hypopharynx 67 41.4 58 46.0
cT-Classiﬁcation#
1, 2 13 8.1 66 52.4
3, 4 148 91.9 60 47.6
cN-Classiﬁcation#
0, 1 14 3.7 50 39.7
2, 3 148 91.3 76 60.3
Stage
≤3 4 3.1 42 33.3
4 157 96.9 84 66.7
Total tumor volume
≤median∗ 52 43.0 52 46.8
>median∗ 69 57.0 59 53.2
R-Classiﬁcation
0 — — 78 65.0
1 — — 37 30.8
2— — 5 4 . 2
Fractionation regimen
Conventional 24 14.8 126 100.0
Concomitant boost 138 85.2 0 0.0
Simultaneous radiochemotherapy
Yes 99 61.1 0 0.0
No 63 38.9 126 100.0
RT interruptions >5d a y s
Yes 36 22.2 24 20.0
No 126 77.8 96 80.0
Interval surgery-RT >32 days
Yes — — 58 47.5
No — — 64 52.5
RT, radiation therapy; ∗median for deﬁnitive RT is 69.4cm3, median for postoperative RT is 21.2cm3.
tumor volume measurements. The method comparison of
the 34 patients showed that the 95% limit of agreement
between the two total tumor volume measurements was
approximately ±150% of the average total tumor volume
measurement of both methods (Figure 4).
4. Discussion
Thisretrospectivesingleinstitutionanalysisinvestigatedpos-
sibleprognosticfactorsofpatientswithsquamouscellcancer
of the oro- and hypopharynx treated with (i) deﬁnitiveJournal of Oncology 5
Table 2: Deﬁnitive radiation therapy: univariate analysis of overall survival, locoregional control, and metastasis-free survival.
Factor
Overall survival Locoregional failure Metastasis
5y-survival P 5y-CIF P 5y-CIF P
Gender
Female 0.15 (95% CI 0.01–0.45) 0.60 (95% CI 0.50–0.68) 0.22 (95% CI 0.04–0.49)
Male 0.28 (95% CI 0.19–0.37) 0.39 0.61 (95% CI 0.52–0.70) 0.52 0.33 (95% CI 0.24–0.42) 0.47
Age (years)
≤56 0.27 (95% CI 0.17–0.39) 0.63 (95% CI 0.51–0.73) 0.34 (95% CI 0.23–0.45)
>56 0.25 (95% CI 0.13–0.40) 0.43 0.63 (95% CI 0.46–0.76) 0.29 0.28 (95% CI 0.17–0.40) 0.61
Hemoglobin level pre-RT
(g/dL)
≤12 0.09 (95% CI 0.01–0.30) 0.82 (95% CI 0.56–0.93) 0.25 (95% CI 0.07–0.48)
>12 0.30 (95% CI 0.20–0.40) 0.02 0.58 (95% CI 0.47–0.67) 0.01 0.33 (95% CI 0.23–0.42) 0.46
Tumor site
Oropharynx 0.24 (95% CI 0.14–0.35) 0.69 (95% CI 0.56–0.78) 0.34 (95% CI 0.24–0.44)
Hypopharynx 0.30 (95% CI 0.17–0.44) 0.70 0.54 (95% CI 0.39–0.67) 0.14 0.28 (95% CI 0.16–0.42) 0.32
T-Classiﬁcation
1, 2 0.44 (95% CI 0.13–0.72) 0.41 (95% CI 0.13–0.67) 0.25 (95% CI 0.05–0.51)
3, 4 0.25 (95% CI 0.17–0.34) 0.34 0.65 (95% CI 0.55–0.73) 0.28 0.33 (95% CI 0.24–0.42) 0.70
N-Classiﬁcation
0, 1 0.52 (95% CI 0.19–0.77) 0.17 (95% CI 0.02–0.43) 0.16 (95% CI 0.02–0.41)
2, 3 0.26 (95% CI 0.17–0.34) 0.17 0.66 (95% CI 0.56–0.74) <0.01 0.33 (95% CI 0.24–0.41) 0.38
Total tumor volume (cm3)
≤68.4 0.36 (95% CI 0.22–0.51) 0.46 (95% CI 0.33–0.59) 0.29 (95% CI 0.15–0.44)
>68.4 0.18 (95% CI 0.09–0.30) <0.01 0.78 (95% CI 0.62–0.88) <0.01 0.37 (95% CI 0.24–0.50) 0.13
Simultaneous
radiochemotherapy
Yes 0.32 (95% CI 0.21–0.42) 0.57 (95% CI 0.46–0.67) 0.37 (95% CI 0.27–0.48)
No 0.17 (95% CI 0.05–0.37) 0.03 0.73 (95% CI 0.53–0.85) 0.08 0.21 (95% CI 0.1–0.34) 0.04
RT interruptions >5d a y s
Yes 0.15 (95% CI 0.01–0.43) 0.58 (95% CI 0.29–0.78) 0.28 (95% CI 0.13–0.44)
No 0.28 (95% CI 0.19–0.38) 0.51 0.64 (95% CI 0.53–0.73) 0.83 0.33 (95% CI 0.23–0.42) 0.96
RT, radiation therapy; CIF, cumulative incidence function; P: P value.
Table 3: Deﬁnitive radiation therapy: multivariate analysis of overall survival, locoregional control, and metastasis-free survival.
Factor
Overall survival Locoregional control Metastasis-free survival
RR P RR P RR P
Gender 1.34 (95% CI 0.62–2.91) 0.46 1.50 (95% CI 0.70–3.24) 0.30 0.79 (95% CI 0.15–4.07) 0.78
Age 1 (95% CI 0.63–1.59) 0.99 1.20 (95% CI 0.74–1.95) 0.45 0.96 (95% CI 0.47–1.98) 0.91
Hemoglobin level pre-RT 0.74 (95% CI 0.41–1.35) 0.33 0.74 (95% CI 0.42–1.31) 0.30 2.79 (95% CI 0.82–9.46) 0.10
Tumor site 1.24 (95% CI 0.76–2.04) 0.39 1.35 (95% CI 0.81–2.25) 0.24 1.40 (95% CI 0.62–3.15) 0.41
T-Classiﬁcation 1.17 (95% CI 0.43–3.13) 0.76 0.75 (95% CI 0.22–2.58) 0.65 1.44 (95% CI 0.29–7.12) 0.66
N-Classiﬁcation 1.14 (95% CI 0.38–3.43) 0.82 5.84 (95% CI 0.88–38.9) 0.07 2.28 (95% CI 0.21–25.1) 0.50
Total tumor volume 2.46 (95% CI 1.47–4.11) <0.01 2.50 (95% CI 1.43–4.36) <0.01 1.59 (95% CI 0.78–3.26) 0.20
Simultaneous
radiochemotherapy 0.52 (95% CI 0.31–0.88) 0.01 0.68 (95% CI 0.40–1.16) 0.15 2.63 (95% CI 1.03–6.73) 0.04
RT interruptions >5 days 0.95 (95% CI 0.5–1.8) 0.88 0.77 (95% CI 0.36–1.66) 0.51 1.08 (95% CI 0.39–3.04) 0.88
RT, radiation therapy; RR, relative risk, P: P-value.6 Journal of Oncology
Table 4: Postoperative radiation therapy: univariate analysis of overall survival, locoregional control, and metastasis-free survival.
Factor
Overall survival Locoregional failure Metastasis
5y-survival P 5y-CIF P 5y-CIF P
Gender
Female 0.89 (95% CI 0.75–1.03) 0.53 (95% CI 0.10–0.85) 0.11 (95% CI 0.02–0.29)
Male 0.66 (95% CI 0.54–0.77) 0.17 0.33 (95% CI 0.23–0.44) 0.56 0.21 (95% CI 0.14–0.30) 0.27
Age (years)
≤56 0.72 (95% CI 0.60–0.84) 0.29 (95% CI 0.17–0.41) 0.21 (95% CI 0.12–0.31)
>56 0.65 (95% CI 0.47–0.82) 0.87 0.45 (95% CI 0.27–0.61) 0.10 0.19 (95% CI 0.09–0.31) 0.85
Hemoglobin level pre-RT
(g/dL)
≤12 0.64 (95% CI 0.46–0.83) 0.41 (95% CI 0.20–0.61) 0.17 (95% CI 0.07–0.31)
>12 0.69 (95% CI 0.55–0.84) 0.72 0.27 (95% CI 0.16–0.40) 0.42 0.23 (95% CI 0.13–0.35) 0.45
Tumor site
Oropharynx 0.72 (95% CI 0.58–0.86) 0.44 (95% CI 0.27–0.59) 0.14 (95% CI 0.07–0.23)
Hypopharynx 0.65 (95% CI 0.51–0.80) 0.35 0.28 (95% CI 0.16–0.41) 0.46 0.27 (95% CI 0.15–0.40) 0.30
T-Classiﬁcation
1, 2 0.69 (95% CI 0.54–0.83) 0.34 (95% CI 0.20–0.49) 0.19 (95% CI 0.11–0.30)
3, 4 0.70 (95% CI 0.56–0.83) 0.80 0.37 (95% CI 0.23–0.52) 0.60 0.20 (95% CI 0.11–0.32) 0.94
N-Classiﬁcation
0, 1 0.72 (95% CI 0.54–0.89) 0.28 (95% CI 0.12–0.48) 0.10 (95% CI 0.04–0.21)
2, 3 0.68 (95% CI 0.55–0.80) 0.24 0.40 (95% CI 0.27–0.53) 0.06 0.26 (95% CI 0.16–0.36) 0.03
R-Classiﬁcation
0 0.68 (95% CI 0.56–0.80) 0.37 (95% CI 0.23–0.50) 0.21 (95% CI 0.11–0.31)
1, 2 0.69 (95% CI 0.59–0.79) 0.95 0.37 (95% CI 0.16–0.58) 0.81 0.20 (95% CI 0.07–0.33) 0.80
Total tumor volume (cm3)
≤21.2 0.65 (95% CI 0.47–0.82) 0.23 (95% CI 0.09–0.37) 0.17 (95% CI 0.07–0.27)
>21.2 0.61 (95% CI 0.45–0.76) 0.13 0.44 (95% CI 0.27–0.60) 0.04 0.26 (95% CI 0.14–0.39) 0.25
RT interruptions >5d a y s
Yes 0.66 (95% CI 0.45–0.87) 0.51 (95% CI 0.26–0.72) 0.25 (95% CI 0.10–0.44)
No 0.70 (95% CI 0.57–0.82) 0.22 0.27 (95% CI 0.17–0.39) 0.10 0.18 (95% CI 0.11–0.27) 0.26
Interval surgery-RT >32 days
Yes 0.66 (95% CI 0.51–0.80) 0.50 0.45 (95% CI 0.28–0.60) 0.40 0.20 (95% CI 0.11–0.32) 0.79
No 0.70 (95% CI 0.54–0.85) 0.27 (95% CI 0.15–0.40) 0.20 (95% CI 0.11–0.32)
RT: radiation therapy; CIF: cumulative incidence function; P: P value.
radiotherapy/radiochemotherapy or (ii) surgery followed by
postoperative radiotherapy. The two patient groups were
analysed separately because they diﬀered considerably in
respect to patient- and treatment-related characteristics and
prognosis.
The tumor volume has been stated to be one of the most
precise and most relevant predictor of radiotherapy outcome
[9]. For patients with oro- and hypopharyngeal cancer
treated with deﬁnitive radiotherapy or radiochemotherapy,
the quantitative tumor volume was identiﬁed as signiﬁcant
prognostic factor in the majority of studies [10–20], and in
few studies, as a prognostic factor of marginal [21, 22]o rn o
signiﬁcance [23].
In the multivariate analysis of our study, the total tumor
volume had a statistically highly signiﬁcant impact on the
overall survival and locoregional control on patients treated
with deﬁnitive radiotherapy/radiochemotherapy.
A new ﬁnding of our study is that the total tumor volume
also had a statistically signiﬁcant impact on the locore-
gional control in patients treated with surgery followed
by postoperative radiotherapy. For this patient group, the
total tumor volume was the only signiﬁcant prognostic
factor in the multivariate analysis. Our data suggest that
the total tumor volume should be used to select patients
for an intensiﬁed deﬁnitive or postoperative adjuvant treat-
ment. Recent randomized studies have shown a signiﬁ-
cantly improved outcome of “high-risk” patients treated
with adjuvant simultaneous radiochemotherapy compared
to adjuvant radiotherapy alone [24, 25]. A comparative
analysis of both studies revealed the extracapsular extension
of tumor from neck nodes and/or microscopically involved
surgical margins as signiﬁcant clinical risk factors for poor
outcome [26]. The quantitative total tumor volume was not
considered in this analysis.Journal of Oncology 7
Table 5: Postoperative radiation therapy: multivariate analysis of overall survival, locoregional control, and metastasis-free survival.
Factor
Overall survival Locoregional control Metastasis-free survival
RR P RR P RR P
Gender 0.34 (95% CI
0.04–2.74) 0.31 0.33 (95% CI
0.05–2.10) 0.24 0.63 (95% CI
0.05–8.47) 0.73
Age 1.11 (95% CI
0.49–2.54) 0.80 2.23 (95% CI
0.93–5.38) 0.07 1.05 (95% CI
0.36–3.04) 0.93
Hemoglobin level pre-RT 0.88 (95% CI
0.40–1.92) 0.75 0.79 (95% CI
0.32–1.93) 0.60 1.42 (95% CI
0.55–3.68) 0.47
Tumor site 0.98 (95% CI
0.42–2.26) 0.95 1.25 (95% CI
0.46–3.42) 0.66 0.65 (95% CI
0.25–1.72) 0.39
T-Classiﬁcation 1.24 (95% CI
0.53–2.88) 0.62 1.85 (95% CI
0.77–4.42) 0.17 1.24 (95% CI
0.47–3.26) 0.66
N-Classiﬁcation 1.17 (95% CI
0.45–3.09) 0.75 1.81 (95% CI
0.61–5.35) 0.28 2.25 (95% CI
0.72–7.01) 0.16
R-Classiﬁcation 1.17 (95% CI
0.50–2.73) 0.72 0.79 (95% CI
0.34–1.87) 0.60 1.04 (95% CI
0.41–2.64) 0.94
Total tumor volume 1.77 (95% CI
0.76–4.14) 0.19 3.19 (95% CI
1.00–10.2) 0.05 1.03 (95% CI
0.37–2.85) 0.95
RT interruptions >5d a y s 1.42 (95% CI
0.57–3.50) 0.45 1.17 (95% CI
0.50–2.70) 0.72 1.15 (95% CI
0.31–4.31) 0.84
Interval surgery-RT >32 days 1.45 (95% CI
0.67–3.13) 0.35 1.92 (95% CI
0.81–4.54) 0.14 0.96 (95% CI
0.38–2.41) 0.93
RT: radiation therapy; RR: relative risk; P: P value.
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Figure 4: Diﬀerence as percentage of the average tumor volume of
the quantitative CT-based tumor volumetry and estimation of the
tumor volume based on the histological report plotted against their
mean.
The only other signiﬁcant prognostic factor in the mul-
tivariate analysis for patients treated with deﬁnitive radio-
therapy in our study was the application of a simultane-
ous chemotherapy. The simultaneous chemotherapy was
signiﬁcantly associated with an improved overall survival
and distant metastasis-free survival and showed a statistical
t r e n do fa ni m p r o v e dl o c o r e g i o n a lc o n t r o l( P = 0.15). This
observation is well in line with the literature. Randomized
clinical trials [27–35] and meta-analyses [36, 37]h a v e
shown a signiﬁcantly improved local control and survival
with deﬁnitive simultaneous radiochemotherapy compared
to deﬁnitive radiotherapy alone in patients with advanced
squamous cell cancer of the head and neck.
Interestingly, in our study, the preradiotherapy hemo-
globin level was a signiﬁcant prognostic factor in the uni-
variate analysis of patients treated with deﬁnitive radiother-
apy/radiochemotherapy but lost its statistical signiﬁcance
in the multivariate analysis. If the total tumor volume was
removed from the multivariate model, the pre-radiotherapy
hemoglobin level retained its signiﬁcance. Our data suggest
that the total tumor volume is the stronger of both prognos-
tic factors. A signiﬁcant association of the pre-radiotherapy
hemoglobin concentration with the treatment outcome after
deﬁnitive radiotherapy/radiochemotherapy in the absence of
quantitative tumor volume data has been reported by several
studies in the literature [38–46].
For patients treated with postoperative radiotherapy, the
pre-radiotherapy hemoglobin level showed no prognostic
signiﬁcance in our study. In the literature, diﬀering ﬁndings
arereported.Onestudyfoundasigniﬁcantimpactofthepre-
radiotherapy hemoglobin level on survival in patients with
head and neck cancer treated with adjuvant radiotherapy
[47]. Other studies evaluated the prognostic signiﬁcance
of the hemoglobin level at diﬀerent time points during
the treatment. In these studies, no prognostic signiﬁcance
was found for the pre-radiotherapy hemoglobin level, but
for the hemoglobin level before surgery [48], after surgery
[49, 50], duration of low hemoglobin level during the
interval between surgery and radiotherapy [48], or for
the diﬀerence of the hemoglobin concentration before and
after adjuvant radiotherapy [51]. Several studies using pO28 Journal of Oncology
histography have shown an impact of the tumor oxygenation
on the survival of patients with head and neck cancer
after radiotherapy [52–55], but no clear correlation was
found between the tumor oxygenation by means of pO2
histography and the hemoglobin concentration [56, 57].
Onmultivariateanalysis,thepotentialprognosticfactors,
gender, age, pre-radiotherapy hemoglobin level, tumor site,
T-andN-,andR-status,RT-interruptions>5days,andinter-
val surgery-RT >32 days, showed no statistical signiﬁcance in
our study.
Other prognostic factors on multivariate analysis for lo-
cally advanced head and neck cancers reported by other
studies were the performance status [45, 46], high-grade
acute organ toxicity [58], or the UICC stage [59].
5. Conclusion
Our data suggest that the total tumor volume is the pre-
dominant prognostic factor in patients with squamous cell
cancer of the oro- and hypopharynx treated with deﬁnitive
radiotherapy/radiochemotherapy or surgery followed by
postoperative radiotherapy. The total tumor volume should
be used to identify high-risk patients and to stratify patients
in clinical trials or statistical analyses.
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